Entries by Ali
Scientist – Synthetic Chemistry
Curve Therapeutics is a venture-backed start-up company based on an innovative approach to targeting challenging disease targets developed by Prof Ali Tavassoli. The platform has been used to identify and report a number of cell-active, first in class inhibitors (including Miranda et al., 2013, J. Am. Chem. Soc. 135, 10418, Leitch et al., 2018, Chem. […]
Curve CSO featured in the “Careers in Drug Discovery” podcast
Our CSO, Prof Ali Tavassoli, discusses his career, academic research and experience with building a Biotech company with Tom Froggatt in the “Careers in Drug Discovery” podcast. Listen to Ali and Tom’s conversation on iTunes or Spotify.
Curve Therapeutics Participates in Parliamentary Meetings
Southampton, UK, 31st July 2019. Curve Therapeutics (Curve) a private biotechnology company pioneering a potentially game-changing, functional drug discovery platform, today announces its participation in the UK BioIndustry Association’s 2021 Parliament Day. This annual event gives senior representatives from the UK biotech sector the opportunity to meet with MPs, Ministers and Peers to discuss key […]
Curve Therapeutics Announces Grant of US Patent
Southampton, UK, 31st March 2021. Curve Therapeutics (Curve) a private biotechnology company pioneering a potentially game-changing, functional drug discovery platform, today announces the grant of US Patent 10,962,549 describing novel Microcycles that inhibit both HIF-1 and HIF-2. Curve originated from world-leading Microcycle® research conducted by Professor Tavassoli’s group in the Department of Chemistry at the […]
Curve Therapeutics Announces Investment from co-lead Epidarex Capital
Southampton, UK, 31st July 2020. Curve Therapeutics (Curve) a private biotechnology company pioneering a potentially game-changing, functional drug discovery platform, today announces an investment of £2.25 Mn from Epidarex Capital, a trans-Atlantic venture capital firm that invests in early-stage, high growth life science and health technology companies in emerging and under-ventured research hubs within the […]
Curve Therapeutics Announces Seed Investment from Advent Life Sciences
Southampton, UK, 27th June 2019. Curve Therapeutics (Curve) a private biotechnology company pioneering a potentially game-changing, functional drug discovery platform, today announces a seed investment of £2.25 Mn from Advent Life Sciences, a leading trans-Atlantic venture investor focused on building innovative Life Sciences businesses in the UK, Europe and the USA. Curve originated from world-leading […]
